Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pneumococcal Vaccine Market Size Changed, over the years?

The market size for the pneumococcal vaccine has seen robust growth in recent years. The market is projected to expand from $8.94 billion in 2024 to $9.49 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the historic period include the discovery of streptococcus pneumoniae, public health concerns, initiatives for early vaccination, advancements in healthcare, and modifications in vaccine policies.

How Much Will the Pneumococcal Vaccine Market Be Worth in 2029?

A significant expansion is anticipated in the pneumococcal vaccine market in the coming years, with projections showing growth to $12.12 billion by 2029, indicative of a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this forecasted growth span from the evolution of pneumococcal strains, ongoing research and development efforts, immunization priorities, enhanced vaccine accessibility, to aging populations. Key trends expected to emerge during this forecast period encompass the development of multivalent vaccines, focusing on vaccination for high-risk groups, efforts to enhance vaccine effectiveness, proliferating education and awareness campaigns, and prioritizing infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Which is the Largest Company in the Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

What Are the Main Market Drivers in the Pneumococcal Vaccine Industry?

The escalating incidence of pneumococcal infections is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal infections, caused by the bacterium Streptococcus pneumoniae or pneumococcus, encompass diseases like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies that will counteract these bacteria, minimizing or eliminating the bacteria and toxins that cause disease. This protects vulnerable groups such as children, the elderly, and those with compromised immune systems from various types of pneumococcal diseases. For instance, as of January 2022, the US Center for Disease Control and Prevention reported that Pneumococcal pneumonia alone is responsible for an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Hence, the rising incidence of pneumococcal contamination is contributing to the growth of the pneumococcal vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

How Is the Pneumococcal Vaccine Market Segments Structured?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Strategic Trends Are Transforming the Pneumococcal Vaccine Market?

Top companies in the pneumococcal vaccine market are launching innovative products to boost their market gains. For instance, the US-based pharmaceutical firm, Merck & Co Inc., unveiled the V116 vaccine in July 2023. The vaccine is designed to treat eight unique serotypes of Streptococcus pneumoniae, the main cause of adult pneumococcal disease. When compared to other similar vaccines, V116 has demonstrated superior immunogenicity across multiple serotypes in adults, and has yielded positive immune reactions in both individuals with no prior vaccination history and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has labelled V116 as a breakthrough therapy and it is presently in the third phase of development.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Global Regions Offer the Highest Growth in the Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

This Report Delivers Insight On:

1. How big is the pneumococcal vaccine market, and how is it changing globally?

2. Who are the major companies in the pneumococcal vaccine market, and how are they performing?

3. What are the key opportunities and risks in the pneumococcal vaccine market right now?

4. Which products or customer segments are growing the most in the pneumococcal vaccine market?

5. What factors are helping or slowing down the growth of the pneumococcal vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model